Approach to Treating Patients with NSCLC with Uncommon EGFR Mutations

Data from the phase 2 SAVANNAH trial may support savolitinib as a new treatment option following standard-of-care osimertinib in EGFR-mutated NSCLC.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Patients with non–small cell lung cancer and larger brain metastases may benefit most from the addition of up-front stereotactic radiosurgery to TKIs.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Data from the LUMINOSITY trial support the application for telisotuzumab vedotin in nonsquamous NSCLC harboring c-Met protein overexpression.

Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.